Evidence map›Paper›PMID 32747012›Full record

ArticleMedicina clinica2020

The effects of renin-angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial.

Haiming Cui, Feng Wu, Zhenyu Fan, Xin Cheng, Jilin Cheng, Min Fan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina clinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Haiming CuiDepartment of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Feng WuDepartment of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhenyu FanDepartment of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xin ChengDepartment of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jilin ChengDepartment of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Electronic address: chengjilin@shphc.org.cn.
Min FanDepartment of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: fanminyueyang@outlook.com.
Shanghai Public Health Clinical Center · CNShanghai University of Traditional Chinese Medicine · CNYueyang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectiveA recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin-angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with hypertension. PATIENTS AND

methodIn this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI.

resultsComparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated.

conclusionsThrough the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms.

Indexed as

BetacoronavirusAdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCase-Control StudiesChinaCoronavirus InfectionsCoughCOVID-19FemaleHumansHypertensionMaleMiddle AgedPandemicsAngiotensin-Converting Enzyme InhibitorsCoronavirus disease 2019Enfermedad Coronavirus 2019HipertensiónHypertensionRenin–angiotensin system inhibitorsRenin-inhibidores del sistema de angiotensina

Identifiers

PMID32747012
PMCPMC7287454
OpenAlexW3035554661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.